Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02168777
Title Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bayer
Indications

lung non-small cell carcinoma

colorectal cancer

breast cancer

Advanced Solid Tumor

Therapies

Refametinib + Regorafenib

Refametinib

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
New Haven Connecticut 06510 United States Details
Detroit Michigan 48201 United States Details
Saint Louis Missouri 63110 United States Details
Chapel Hill North Carolina 27599 United States Details
Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field